公开(公告)号：US11311504B2

公开(公告)日：2022-04-26

申请号：US16502651

申请日：2019-07-03

申请人： Gruenenthal GmbH

发明人： Stefanie Frosch ,  Klaus Linz ,  Klaus Schiene

IPC分类号： A61K31/167 ,  A61K31/407 ,  A61K31/223

摘要： The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from paracetamol and propacetamol.

公开(公告)号：US10829480B2

公开(公告)日：2020-11-10

申请号：US16265080

申请日：2019-02-01

申请人： GRUENENTHAL GMBH

发明人： Sven Kuehnert ,  Rene Michael Koenigs ,  Achim Kless ,  Anita Wegert ,  Paul Ratcliffe ,  Ruth Jostock ,  Thomas Koch ,  Klaus Linz ,  Wolfgang Schroeder ,  Klaus Schiene ,  Ingo Konetzki

IPC分类号： C07D405/06 ,  C07D235/02 ,  C07D401/06 ,  C07D403/06

摘要： The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

公开(公告)号：US10813890B2

公开(公告)日：2020-10-27

申请号：US15674407

申请日：2017-08-10

申请人： Gruenenthal GmbH

发明人： Klaus Schiene ,  Petra Bloms-Funke

IPC分类号： A61K31/137 ,  A61K31/136 ,  A61K31/192 ,  A61K45/06 ,  A61K31/13 ,  A61K31/135

摘要： A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.

公开(公告)号：US10398657B2

公开(公告)日：2019-09-03

申请号：US15243271

申请日：2016-08-22

申请人： Gruenenthal GmbH

发明人： Klaus Schiene ,  Ilona Steigerwald ,  Michel Hamon ,  Johannes Schneider ,  Silvia Reinartz ,  Ulrich Jahnel ,  Thomas Tzschentke

IPC分类号： A61K31/137 ,  A61K9/00 ,  A61P25/04

摘要： The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine.

公开(公告)号：US10076510B2

公开(公告)日：2018-09-18

申请号：US15075606

申请日：2016-03-21

申请人： Gruenenthal GmbH

发明人： Stefanie Frosch ,  Klaus Linz ,  Klaus Schiene

IPC分类号： A61K31/407 ,  A61K31/192

CPC分类号： A61K31/407 ,  A61K31/192 ,  A61K2300/00

摘要： The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.

公开(公告)号：US10471079B2

公开(公告)日：2019-11-12

申请号：US15175564

申请日：2016-06-07

申请人： GRUENENTHAL GmbH

发明人： Klaus Schiene ,  Guenter Haase ,  Babette-Yvonne Koegel ,  Elmar Friderichs ,  Ulrich Jahnel

IPC分类号： A61K31/635 ,  A61K31/135 ,  A61K31/341 ,  A61K31/415 ,  A61K31/137 ,  A61K31/365

摘要： Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain.

公开(公告)号：US10206890B2

公开(公告)日：2019-02-19

申请号：US14927585

申请日：2015-10-30

申请人： Gruenenthal GmbH

发明人： Klaus Schiene ,  Petra Bloms-Funke ,  Thomas Christoph

IPC分类号： A61K31/137 ,  A61K31/165 ,  A61K31/197 ,  A61K31/205 ,  A61K31/27 ,  A61K31/4015 ,  A61K31/522 ,  A61K31/53 ,  A61K31/70 ,  A61K45/06

摘要： A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

公开(公告)号：US09855286B2

公开(公告)日：2018-01-02

申请号：US13892813

申请日：2013-05-13

申请人： Gruenenthal GmbH

发明人： Stefanie Frosch ,  Klaus Linz ,  Klaus Schiene

IPC分类号： A61K31/407 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06

CPC分类号： A61K31/616 ,  A61K31/407 ,  A61K31/60 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof.

公开(公告)号：US20190274974A1

公开(公告)日：2019-09-12

申请号：US16423423

申请日：2019-05-28

申请人： GRUENENTHAL GMBH

发明人： Thomas CHRISTOPH ,  Jean De Vry ,  Thomas Tzschentke ,  Petra Bloms-Funke ,  Klaus Schiene ,  Michel Hamon

IPC分类号： A61K31/137

摘要： The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia.

公开(公告)号：US09308196B2

公开(公告)日：2016-04-12

申请号：US13892362

申请日：2013-05-13

申请人： Gruenenthal GmbH

发明人： Stefanie Frosch ,  Klaus Linz ,  Klaus Schiene

IPC分类号： A61K31/407 ,  A61K31/5415

CPC分类号： A61K31/407 ,  A61K31/5415 ,  A61K2300/00

摘要： The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.

摘要翻译： 本发明涉及包含第一药理活性成分的药物组合物，其选自（1r，4r）-6'-氟-N，N-二甲基-4-苯基-4'，9'-二氢-3'H - 螺[环己烷-1,1'-吡喃并[3,4，b]吲哚] -4-胺及其生理上可接受的盐，以及第二药理活性成分，其是选自美洛昔康， 吡罗昔康，替诺昔康，氯诺昔康及其生理上可接受的盐。